Renaissance Technologies LLC Has $588.75 Million Stock Holdings in Exelixis, Inc. $EXEL

Renaissance Technologies LLC reduced its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 1.3% during the 1st quarter, Holdings Channel reports. The fund owned 13,726,993 shares of the biotechnology company’s stock after selling 187,050 shares during the quarter. Exelixis makes up approximately 0.9% of Renaissance Technologies LLC’s portfolio, making the stock its 7th biggest position. Renaissance Technologies LLC owned about 0.05% of Exelixis worth $588,751,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after purchasing an additional 19,407 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Exelixis by 4.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after purchasing an additional 68,133 shares in the last quarter. Focus Partners Wealth grew its holdings in shares of Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 17,483 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Exelixis by 134.3% during the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC increased its stake in shares of Exelixis by 23.8% in the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after buying an additional 2,764 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Down 0.5%

EXEL stock opened at $55.37 on Friday. The company has a market cap of $13.92 billion, a P/E ratio of 18.40, a PEG ratio of 1.60 and a beta of 0.42. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $57.57. The business has a fifty day moving average of $53.16 and a 200-day moving average of $47.19.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. The firm had revenue of $610.81 million during the quarter, compared to analyst estimates of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The company’s revenue was up 10.0% on a year-over-year basis. During the same period last year, the company earned $0.55 earnings per share. As a group, equities research analysts anticipate that Exelixis, Inc. will post 3.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Patrick J. Haley sold 32,110 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total value of $1,599,399.10. Following the transaction, the executive vice president owned 357,638 shares of the company’s stock, valued at approximately $17,813,948.78. This trade represents a 8.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Dana Aftab sold 43,451 shares of Exelixis stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the sale, the executive vice president owned 594,741 shares of the company’s stock, valued at approximately $29,945,209.35. This represents a 6.81% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 219,170 shares of company stock worth $10,620,641. 2.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on EXEL shares. Citizens Jmp lifted their price target on Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a report on Wednesday, June 24th. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Royal Bank Of Canada raised their price objective on shares of Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. UBS Group reaffirmed a “buy” rating on shares of Exelixis in a research note on Thursday, July 2nd. Finally, Barclays upped their target price on shares of Exelixis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 14th. Nine analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $49.00.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.